BRAF and neoplasm: Until this issue is clarified in larger series, one should not exclude a patient with an early‐onset CRC from MLH1 constitutional methylation testing based on the detection of a BRAF mutation in the tumor, as is currently common practice when selecting patients for MLH1 germline mutation analysis.